[Nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: focus on calciomimetics]

Area of Science:

• Endocrinology
• Nephrology
• Bone Metabolism

Background:

• Primary hyperparathyroidism (PHPT) disrupts calcium homeostasis, leading to abnormal parathyroid hormone (PTH) levels.
• Key complications include nephrolithiasis (kidney stones) and fibrocystic bone disease.
• While surgery is curative, medical therapy is an alternative for specific patient groups.

Purpose of the Study:

• To review current medical therapies for PHPT, focusing on bisphosphonates and calcimimetics.
• To explore the potential efficacy of cinacalcet in PHPT patients with nephrolithiasis.
• To evaluate the rationale for combining cinacalcet and bisphosphonates for complex PHPT cases.

Main Methods:

• Review of existing pharmacological treatments for PHPT.
• Analysis of preliminary data on cinacalcet's effect on nephrolithiasis in PHPT.
• Consideration of drug mechanisms for bone and calcium metabolism.

Main Results:

• Cinacalcet effectively reduces calcemia in most PHPT patients.
• Preliminary data suggests cinacalcet may benefit PHPT patients with nephrolithiasis.
• Bisphosphonates, particularly alendronate, improve bone mass.

Conclusions:

• Medical therapy with bisphosphonates and/or cinacalcet offers alternatives to surgery for PHPT.
• Combining cinacalcet and bisphosphonates may be beneficial for PHPT patients with both bone loss and nephrolithiasis who are not surgical candidates.